Sorafenib
- This topic has 1 reply, 2 voices, and was last updated 13 years, 7 months ago by
.
-
Posts
-
Money blocks the way again. Thats a real problem in socialist medical systems is that budgets are always at the mercy of bureaucrats in more ways than you can count. The same problems occur here in Canada and we could discuss this all night long and argue the merits of social medicine and private medicine.
I’m a Canadian and I was treated at the Mayo Clinic in the U.S. It was there that my health care system of my province did fund my CC and liver transplant costs. Unfortunately I saw many U.S. patients struggle with their private insurers to the point of tears.
Its 6 of one and half dozen of the other about government and private health care systems.
Raye
The European Commission granted marketing authorization for the drug for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer in October 2007, [6], and approval Following the FDA for this indication in November 2007. [7]
In November 2009, the UK’s National Institute of Clinical Excellence Declined to approve the drug for use Within The NHS in England, Wales and Northern Ireland, Stating That ITS effectiveness (Increasing survival in primary liver cancer by 6 months) did not justify ITS high price , at up to
- The forum ‘Chemotherapy & More’ is closed to new topics and replies.